If you have been reading about Mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
Documentation supports reproducibility and traceability. Records often include lot number, solvent composition, final concentration, preparation date, and storage location. Such details help distinguish procedural variation from actual sample instability. Questions remain about how best to predict long-term stability from short-term accelerated studies, because peptide degradation pathways differ widely. For many peptides, the relationship between in vitro solution stability and biological behavior is incompletely understood and is an active area of research.
After reconstitution, a peptide solution is typically stored under conditions that limit degradation. Cool temperatures slow hydrolysis and oxidation, while freezing can preserve samples for longer periods. Repeated freeze-thaw cycles may promote aggregation or precipitation, so aliquoting before freezing is a common laboratory practice. The optimal storage temperature depends on the peptide sequence, buffer composition, and expected duration. Solutions containing oxidizable residues may benefit from inert gas overlays or antioxidants, though compatibility with the specific peptide must be considered.
Aseptic technique matters because aqueous peptide solutions can support microbial growth. Sterile solvents, clean workspaces, and sterile filtration can reduce contamination. The choice of filter material and pore size must avoid peptide loss through adsorption, especially for hydrophobic or low-concentration samples. Visual inspection for particles, turbidity, or color change provides a simple initial check, but it cannot confirm identity or purity. Analytical methods such as reversed-phase high-performance liquid chromatography and mass spectrometry are used to verify composition and detect degradation products.
The concentration of a reconstituted peptide is calculated from the mass of peptide powder and the volume of solvent added. This calculation assumes the powder contains only peptide, but many preparations include counterions, water, or salts. Analytical methods such as ultraviolet absorbance or amino acid analysis can estimate actual peptide content. The relationship between nominal and actual concentration is an area where measurements matter. Open questions remain about how aggregation changes the effective concentration in solution.
Peptide reconstitution is the process of dissolving a lyophilized peptide in a liquid to form a solution for later use. Lyophilization removes water under vacuum, leaving a dry powder or porous cake. Reconstitution reintroduces solvent so the peptide molecules return to a dissolved state. The solvent may be purified water, a buffer, or a mixture containing an organic co-solvent. The choice depends on the peptide sequence, its charge, and its hydrophobicity.
During reconstitution, solvent penetrates the dry cake and breaks intermolecular contacts that held the peptide in solid form. Dissolution occurs as individual peptide molecules become surrounded by solvent. Hydrophobic regions can associate with one another instead of dissolving, which may produce turbidity or aggregates. pH and ionic strength influence the charge state of ionizable groups and therefore solubility. Buffer salts can help maintain a stable pH, but they can also participate in interactions that affect the final solution.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature (lyophilized) | -20 °C or lower | Desiccant and sealed container limit moisture |
| Typical storage temperature (reconstituted) | 2-8 °C short term; frozen for longer | Freeze-thaw cycles may damage peptide |
| Appearance of solution | Clear to slightly opalescent | Turbidity or particles suggest aggregation or contamination |
| Identity method | Mass spectrometry | Confirms molecular mass and detects modifications |
| Purity method | Reversed-phase HPLC | Separates peptide from related impurities |
Once reconstituted, a peptide solution is generally less stable than the dry powder. Hydrolysis, oxidation, aggregation, and microbial growth can change the preparation over time, so storage temperature and duration are practical concerns. Dividing a solution into single-use aliquots before freezing can reduce repeated freeze-thaw cycles, which may otherwise cause precipitation or loss of activity. The optimal storage conditions vary by peptide, and no single rule applies to all sequences. Records of solvent, concentration, date, and storage history help maintain traceability. Studies often report stability under defined conditions rather than universal shelf lives.
Reconstitution is the process of dissolving a lyophilized peptide powder in a suitable liquid to produce a solution for laboratory or clinical use. The dry powder is typically a porous cake or fluffy solid formed by freeze-drying an aqueous or mixed-solvent preparation. Adding solvent restores the peptide to a dissolved state, but the result is not necessarily identical to the original pre-lyophilization solution. Factors such as pH, ionic strength, temperature, and the peptide's sequence influence how completely and quickly dissolution occurs. The term is distinct from dilution, which lowers concentration without changing the physical state of an already dissolved material.
Solvent selection depends on the peptide's charge, hydrophobicity, and intended application. Many lyophilized peptides dissolve readily in water, while others require a small amount of a miscible organic solvent, a dilute acid, or a dilute base before aqueous dilution. A buffer may be used when a stable pH range is known, but adding buffer salts can also promote aggregation or precipitation. Dissolution should be observed rather than assumed, because a clear solution does not prove that the peptide is monomeric or fully active. The order of solvent addition and the final volume matter for achieving the intended concentration.
Analytical checks can detect changes in a reconstituted stock over time. Reverse-phase high-performance liquid chromatography can show loss of main peak, new impurity peaks, or altered retention. Mass spectrometry confirms molecular identity and can reveal modifications. Visual inspection for particles, color change, or turbidity provides a simple first check. If a solution shows signs of degradation or contamination, it is typically discarded rather than re-purified in a routine laboratory.
Once a peptide is dissolved, its solution is generally less stable than the dry powder. Chemical pathways such as hydrolysis, oxidation, and deamidation can alter the molecule, while physical processes can form aggregates or cause adsorption to container walls. The rate depends on pH, buffer composition, temperature, concentration, and the specific sequence. Aqueous stocks are therefore kept cold and used within a defined period. Stability testing is usually performed for each peptide rather than assumed from a general rule.
Cold storage slows most degradation but does not stop it. Reconstituted solutions are commonly divided into aliquots and held at -20 °C or -80 °C, depending on the peptide. Repeated freeze-thaw cycles can promote aggregation or precipitation, so single-use aliquots are preferred. Some peptides tolerate refrigeration for short intervals, while others require freezing immediately. Light-sensitive residues may need amber or foil-wrapped containers. The optimal condition remains peptide-specific and should be supported by stability data.
Container selection matters because peptides can adsorb to glass, plastic, and filter membranes. Low-binding polypropylene tubes reduce losses for hydrophobic sequences, and filtration through a 0.22 µm membrane can remove particulates and microorganisms. Some peptides may bind to certain filter materials, so compatibility should be checked. Aliquots should be prepared before freezing to avoid repeated temperature cycling. Labels should record the peptide identity, lot number, solvent, concentration, reconstitution date, and storage condition.
After reconstitution, the peptide solution is less stable than the dried powder because water enables hydrolysis, oxidation, and microbial growth. Storage temperature, pH, buffer composition, and container material all affect how long the solution remains usable. Many peptides are kept at 2–8 °C for short-term work, while frozen aliquots at −20 °C or below are used for longer intervals. Repeated freeze-thaw cycles can cause aggregation or precipitation. The choice of storage condition should be based on stability data for the specific peptide.
Quality checks after reconstitution include visual inspection, pH measurement, and analytical methods such as reversed-phase high-performance liquid chromatography. These tests can detect insoluble material, degradation products, and changes in concentration. Mass spectrometry is often used to confirm molecular identity when the peptide sequence is known. Because a clear solution can still contain aggregates or modified peptide, visual clarity alone is not sufficient. Analytical results are compared with a reference standard or the pre-reconstitution certificate of analysis.
Reconstitution involves considerably more than simply adding liquid. The solid must wet completely, and gentle mixing should avoid foaming, which can denature some peptides. Insoluble particles may indicate incomplete dissolution, aggregation, or insoluble excipients. The resulting concentration is calculated from the weighed peptide mass and the final volume, not from the volume of liquid added alone. Because peptides can adsorb to surfaces, container material and transfer steps can influence recovery, especially at low concentrations.
Peptide reconstitution refers to dissolving a dried peptide preparation in a liquid to form a solution. The dried form is often produced by lyophilization, a process that removes water under vacuum from a frozen sample. This yields a porous cake or powder that is more stable for transport and storage than many liquid formulations. The term reconstitution is also often used for other dried biological materials, so context matters greatly.
The choice of liquid depends on peptide sequence, counterion content, and intended analysis. Water is sufficient for many hydrophilic peptides, while hydrophobic sequences may need a small amount of organic solvent or a buffer. pH can affect charge, solubility, and stability, so the target value is usually selected for the specific peptide. Exact laboratory protocols vary by supplier and application, and no single solvent reliably works for every different peptide.
intensive property A physical quantity whose value does not depend on the size of the system or the quantity of matter for which it is measured. Examples include density, temperature, and pressure. Contrast extensive property.
== Chemical mechanism == An important goal of measuring enzyme kinetics is to determine the chemical mechanism of an enzyme reaction, i.e., the sequence of chemical steps that transform substrate into product. The kinetic approaches discussed above will show at what rates intermediates are formed and inter-converted, but they cannot identify exactly what these intermediates are. Kinetic measurements taken under various solution conditions or on slightly modified enzymes or substrates often shed light on this chemical mechanism, as they reveal the rate-determining step or intermediates in the reaction. For example, the breaking of a covalent bond to a hydrogen atom is a common rate-determining step. Which of the possible hydrogen transfers is rate determining can be shown by measuring the kinetic effects of substituting each hydrogen by deuterium, its stable isotope. The rate will change when the critical hydrogen is replaced, due to a primary kinetic isotope effect, which occurs because bonds to deuterium are harder to break than bonds to hydrogen. It is also possible to measure similar effects with other isotope substitutions, such as 13C/12C and 18O/16O, but these effects are more subtle. Isotopes can also be used to reveal the fate of various parts of the substrate molecules in the final products. For example, it is sometimes difficult to discern the origin of an oxygen atom in the final product, since it may have come from water or from part of the substrate.
The trachea (pl.: tracheae or tracheas), also known as the windpipe, is a cartilaginous tube that connects the larynx to the bronchi of the lungs, allowing the passage of air, and so is present in almost all land vertebrate animals' lungs. The trachea extends from the larynx and branches into the two primary bronchi. At the top of the trachea, the cricoid cartilage attaches it to the larynx. The trachea is formed by a number of horseshoe-shaped rings, joined together vertically by overlying ligaments, and by the trachealis muscle at their ends. The epiglottis closes the opening to the larynx during swallowing. The trachea begins to form in the second month of embryo development, becoming longer and more fixed in its position over time. Its epithelium is lined with column-shaped cells that have hair-like extensions called cilia, with scattered goblet cells that produce protective mucins. The trachea can be affected by inflammation or infection, usually as a result of a viral illness affecting other parts of the respiratory tract, such as the larynx and bronchi, called croup, that can result in a cough. Infection with bacteria usually affects the trachea only and can cause narrowing or even obstruction. As a major part of the respiratory tract, the trachea, when obstructed, prevents air from entering the lungs; thus, a tracheostomy may be required. Additionally, during surgery, if mechanical ventilation is required during anaesthesia, a tube is inserted into the trachea: this is called tracheal intubation.
=== Controlled release of therapeutics === The ability of aptamers to reversibly bind molecules such as proteins has generated increasing interest in using them to facilitate controlled release of therapeutic biomolecules, such as growth factors. This can be accomplished by tuning the binding strength to passively release the growth factors, along with active release via mechanisms such as hybridization of the aptamer with complementary oligonucleotides or unfolding of the aptamer due to cellular traction forces.
=== Platelet-rich plasma === Platelet-rich plasma is under preliminary research for its possible use in treating alopecia areata. A minimum of 3 treatments, once a month for 3 months are recommended, and afterwards a 3-6 month period of continual appointments for maintenance. Factors that determine efficacy include number of sessions, double versus single centrifugation, age and gender, and where the platelet-rich plasma is inserted. Future larger randomized controlled trials and other high-quality studies are still recommended to be carried out and published for a stronger consensus. Further development of a standardized practice for the procedure is also recommended.
Sources: en.wikipedia.org
=== EC 1.7.2 With a cytochrome as acceptor === EC 1.7.2.1: nitrite reductase (NO-forming) EC 1.7.2.2: nitrite reductase (cytochrome; ammonia-forming) EC 1.7.2.3: trimethylamine-N-oxide reductase EC 1.7.2.4: nitrous-oxide reductase EC 1.7.2.5: nitric oxide reductase (cytochrome c) EC 1.7.2.6: hydroxylamine dehydrogenase EC 1.7.2.7: hydrazine synthase EC 1.7.2.8: hydrazine dehydrogenase
Self-assembly is a scalable and parallel process which can involve large numbers of components in a short timeframe. Can result in structural dimensions across orders of magnitude, from nanoscale to macroscale. Is relatively inexpensive compared to the top-down assembly approach, which often consumes large amounts of finite resources. Natural processes that drive self-assembly tend to be highly reproducible. The existence of life is strongly dependent on the reproducibility of self-assembly. Challenges There exist several outstanding challenges in self-assembly, due to a variety of competing factors. Currently self-assembly is difficult to control on large scales, and to be widely applied we will need to ensure high degrees of reproducibility at these scales. The fundamental thermodynamic and kinetic mechanisms of self-assembly are poorly understood - the basic principles of atomistic and macroscale processes can be significantly different than those for nanostructures. Concepts related to thermal motion and capillary action influence equilibrium timescales and kinetic rates that are not well defined in self-assembling systems. Top-down vs bottom-up synthesis
=== Blue Men of Lurgan === The "blue men of Lurgan" were a pair of Lurgan men suffering from what was described as "familial idiopathic methemoglobinemia" who were treated by James Deeny in 1942. Deeny, who would later become the Chief Medical Officer of the Republic of Ireland, prescribed a course of ascorbic acid and sodium bicarbonate. In case one, by the eighth day of treatments, there was a marked change in appearance, and by the twelfth day of treatment, the patient's complexion was normal. In case two, the patient's complexion reached normality over a month-long duration of treatment.
Day of Defeat was followed by Day of Defeat: Source, a remake of the game that runs on Valve's Source engine. The Source remake included significant changes to Day of Defeat's gameplay, new maps, updated graphics, and improved physics. Released on September 26, 2005 to favorable reviews, the game was praised for its gameplay, audio, and graphics. Post-release, the game was supported by Valve with a number of subsequent updates, including versions of the game for OS X and Linux released in 2010 and 2013 respectively.
Peptide PHI, also known as peptide histidine isoleucine, is a peptide which functions as a hormone. This peptide contains a composition of 27 amino acids with histidine on the N-terminus and isoleucine on the C-terminus. It was originally isolated from the mammalian small intestine amongst mammalian neurons called intramural neurons which function in the motor activity of the intestinal walls. An example of this was revealed in a study that demonstrated that this peptide regulates water and electrolyte transportation in the human jejunum; similar to its inhibitory effects on fluid absorption in the small intestine of pigs and rats. Peptide histidine isoleucine (PHI) is part of family that plays a vital role in the cell growth rate such as in the intestine as well as in brain. It was derived from glucagon family called the pituitary adenylate cyclase-activating polypeptide (PACAP) and it has an amino acid sequence homology to vasoactive intestinal peptide, secretin, glucagon, and other growth hormone releasing factor. Human studies have shown that the release of PHI into the stomach regulates the neuroendocrine cell processes that affect gastrointestinal physiology. This peptide is present within the central nervous system that help regulate food consumption behavior, while at peripheral nervous system this peptide accumulates in the stomach which controls the digestion of food. It also plays a role in the regulation of prolactin in humans.
Sources: en.wikipedia.org
Short-term storage is often at refrigerated temperatures, while longer storage may use freezing. Repeated freeze-thaw cycles are generally avoided because they can promote aggregation. Container material and headspace can also affect stability.
Mass spectrometry is commonly used to confirm molecular mass and detect modifications. Reversed-phase high-performance liquid chromatography can assess purity and separate related impurities. These methods are complementary rather than interchangeable.
Turbidity can indicate aggregation, precipitation, or microbial contamination. It may also result from incomplete dissolution or undissolved excipients. The cause is not identifiable from appearance alone.
Lyophilization removes water to produce a dry peptide preparation. Reconstitution adds a solvent back to that preparation to create a liquid solution. The two processes are complementary steps in the lifecycle of many peptide products.